| Host |
Rabbit |
| Klon |
ZR201 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1500-2000) of human MUC4 protein |
| Lokalisation |
Cytoplasm |
MUC-4
|
Zeta Corporation |
ZR201 |
0.1 ml |
Concentrate |
CE/IVD |
Z2520RT |
-
|
| Host |
Mouse |
| Klon |
ZM148 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Gastric carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
M1 mucin preparation from the fluid of an ovarian mucinous cyst belonging to an O Le(a-b) patient |
| Lokalisation |
Cell membrane |
MUC-5AC
|
Zeta Corporation |
ZM148 |
1.0 ml |
Concentrate |
CE/IVD |
Z2461ML |
-
|
| Host |
Mouse |
| Klon |
ZM148 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Gastric carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
M1 mucin preparation from the fluid of an ovarian mucinous cyst belonging to an O Le(a-b) patient |
| Lokalisation |
Cell membrane |
MUC-5AC
|
Zeta Corporation |
ZM148 |
7 ml |
Ready-to-use |
CE/IVD |
Z2461MP |
-
|
| Host |
Mouse |
| Klon |
ZM148 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Gastric carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
M1 mucin preparation from the fluid of an ovarian mucinous cyst belonging to an O Le(a-b) patient |
| Lokalisation |
Cell membrane |
MUC-5AC
|
Zeta Corporation |
ZM148 |
0.5 ml |
Concentrate |
CE/IVD |
Z2461MS |
-
|
| Host |
Mouse |
| Klon |
ZM148 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Gastric carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
M1 mucin preparation from the fluid of an ovarian mucinous cyst belonging to an O Le(a-b) patient |
| Lokalisation |
Cell membrane |
MUC-5AC
|
Zeta Corporation |
ZM148 |
0.1 ml |
Concentrate |
CE/IVD |
Z2461MT |
-
|
| Host |
Mouse |
| Klon |
ZM89 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Stomach. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment covering tandem repeats of human MUC-6 protein |
| Lokalisation |
Cytoplasm |
MUC-6
|
Zeta Corporation |
ZM89 |
1.0 ml |
Concentrate |
CE/IVD |
Z2399ML |
-
|
| Host |
Mouse |
| Klon |
ZM89 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Stomach. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment covering tandem repeats of human MUC-6 protein |
| Lokalisation |
Cytoplasm |
MUC-6
|
Zeta Corporation |
ZM89 |
7 ml |
Ready-to-use |
CE/IVD |
Z2399MP |
-
|
| Host |
Mouse |
| Klon |
ZM89 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Stomach. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment covering tandem repeats of human MUC-6 protein |
| Lokalisation |
Cytoplasm |
MUC-6
|
Zeta Corporation |
ZM89 |
0.5 ml |
Concentrate |
CE/IVD |
Z2399MS |
-
|
| Host |
Mouse |
| Klon |
ZM89 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Stomach. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant fragment covering tandem repeats of human MUC-6 protein |
| Lokalisation |
Cytoplasm |
MUC-6
|
Zeta Corporation |
ZM89 |
0.1 ml |
Concentrate |
CE/IVD |
Z2399MT |
-
|
| Host |
Mouse |
| Klon |
996/1 |
| Format |
Purified |
| Methode |
F, P, WB |
| Positivkontrolle |
Normal colon |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
MUC2 tandem repeat peptide |
MUC2 (Mucin 2)
|
Zytomed Systems GmbH |
996/1 |
200 µg |
Purified |
RUO |
613-0273 |
-
|
| Host |
Mouse |
| Klon |
Ccp58 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthetic peptide representing a region on the Muc-2 glycoprotein |
| Lokalisation |
Cell membrane |
MUC2 (Mucin 2)
|
Zeta Corporation |
Ccp58 |
1 ml |
Concentrate |
CE/IVD |
Z2151ML |
-
|
| Host |
Mouse |
| Klon |
Ccp58 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthetic peptide representing a region on the Muc-2 glycoprotein |
| Lokalisation |
Cell membrane |
MUC2 (Mucin 2)
|
Zeta Corporation |
Ccp58 |
7 ml |
Ready-to-use |
CE/IVD |
Z2151MP |
-
|
| Host |
Mouse |
| Klon |
Ccp58 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthetic peptide representing a region on the Muc-2 glycoprotein |
| Lokalisation |
Cell membrane |
MUC2 (Mucin 2)
|
Zeta Corporation |
Ccp58 |
0.5 ml |
Concentrate |
CE/IVD |
Z2151MS |
-
|
| Host |
Mouse |
| Klon |
Ccp58 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Synthetic peptide representing a region on the Muc-2 glycoprotein |
| Lokalisation |
Cell membrane |
MUC2 (Mucin 2)
|
Zeta Corporation |
Ccp58 |
0.1 ml |
Concentrate |
CE/IVD |
Z2151MT |
-
|
| Host |
Rabbit |
| Klon |
SP241 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung Adenocarcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human MUC-4 protein |
| Lokalisation |
Cell membrane, Cytoplasm |
MUC4 (Mucin 4)
|
Zytomed Systems GmbH |
SP241 |
0.1 ml |
Concentrate |
RUO |
513-5410 |
-
|
| Host |
Rabbit |
| Klon |
SP241 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung Adenocarcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human MUC-4 protein |
| Lokalisation |
Cell membrane, Cytoplasm |
MUC4 (Mucin 4)
|
Zytomed Systems GmbH |
SP241 |
0.5 ml |
Concentrate |
RUO |
513-5412 |
-
|
| Host |
Rabbit |
| Klon |
SP241 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Lung Adenocarcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human MUC-4 protein |
| Lokalisation |
Cell membrane, Cytoplasm |
MUC4 (Mucin 4)
|
Zytomed Systems GmbH |
SP241 |
1 ml |
Concentrate |
RUO |
513-5414 |
-
|
| Host |
Mouse |
| Klon |
45M1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Stomach |
| Verdünnung |
1:50 - 1:75 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, Cell Surface |
MUC5AC (Mucin 5AC)
|
Diagnostic Biosystems |
45M1 |
1 ml |
Concentrate |
CE/IVD |
MOB357 |
-
|
| Host |
Mouse |
| Klon |
45M1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Stomach |
| Verdünnung |
1:50 - 1:75 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, Cell Surface |
MUC5AC (Mucin 5AC)
|
Diagnostic Biosystems |
45M1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB357-01 |
-
|
| Host |
Mouse |
| Klon |
45M1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Stomach |
| Verdünnung |
1:50 - 1:75 |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, Cell Surface |
MUC5AC (Mucin 5AC)
|
Diagnostic Biosystems |
45M1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB357-05 |
-
|
| Host |
Mouse |
| Klon |
45M1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Stomach |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Cytoplasmic, Cell Surface |
MUC5AC (Mucin 5AC)
|
Diagnostic Biosystems |
45M1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM163 |
-
|
| Host |
Mouse |
| Klon |
45M1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA o Citrate |
| Positivkontrolle |
Stomach |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgM |
| Verdünnung |
MUC5AC |
| Lokalisation |
Cytoplasmic |
Mucin 5AC (Gastric Mucin)
|
Biocare Medical |
45M1 |
0.1 ml |
Concentrate |
CE/IVD |
CM231A |
-
|
| Host |
Rabbit |
| Klon |
BC5 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus, cytoplasm |
MUM-1 Protein
|
Biocare Medical |
BC5 |
0.1 ml |
Concentrate |
CE/IVD |
CRM352A |
-
|
| Host |
Rabbit |
| Klon |
BC5 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus, cytoplasm |
MUM-1 Protein
|
Biocare Medical |
BC5 |
0.5 ml |
Concentrate |
CE/IVD |
CRM352B |
-
|
| Host |
Mouse |
| Klon |
MUM1p |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
MUM-1 Protein
|
Diagnostic Biosystems |
MUM1p |
1 ml |
Concentrate |
CE/IVD |
MOB420 |
-
|
| Host |
Mouse |
| Klon |
MUM1p |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
MUM-1 Protein
|
Diagnostic Biosystems |
MUM1p |
0.1 ml |
Concentrate |
CE/IVD |
MOB420-01 |
-
|
| Host |
Mouse |
| Klon |
MUM1p |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
MUM-1 Protein
|
Diagnostic Biosystems |
MUM1p |
0.5 ml |
Concentrate |
CE/IVD |
MOB420-05 |
-
|
| Host |
Mouse |
| Klon |
MUM1p |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
ready-to-use |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
MUM-1 Protein
|
Diagnostic Biosystems |
MUM1p |
6 ml |
Concentrate |
CE/IVD |
PDM420 |
-
|
| Host |
Rabbit |
| Klon |
BC5 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus, cytoplasm |
MUM-1 Protein
|
Biocare Medical |
BC5 |
6 ml |
Ready-to-use |
CE/IVD |
PRM352AA |
-
|
| Host |
Rabbit |
| Klon |
SP114 |
| Reaktivität |
BV,CK,DG,MS,RB,RT |
| Methode |
IHC-P, WB |
| Verdünnung |
1:100 |
MUM1 / IRF4
|
Zytomed Systems GmbH |
SP114 |
0.5 ml |
- |
RUO |
513-4142 |
-
|
| Host |
Rabbit |
| Klon |
SP114 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Hodgkin´s Lymphoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near C-terminus of human MUM1/IRF4 |
| Lokalisation |
Nucleus |
MUM1 / IRF4
|
Zytomed Systems GmbH |
SP114 |
1 ml |
Concentrate |
RUO |
513-4144 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
P |
| Positivkontrolle |
infected tissue |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Purified PPD from M. tuberculosis |
Mycobacterium tuberculosis
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
613-0282 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
- |
| Positivkontrolle |
Tubercolosis infected lung |
| Verdünnung |
1:500 - 1:1000 |
| Isotyp |
not determined |
| Lokalisation |
Bacterial rods and byproducts |
Mycobacterium tuberculosis
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
ACI140A |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
- |
| Positivkontrolle |
Tubercolosis infected lung |
| Verdünnung |
1:500 - 1:1000 |
| Isotyp |
not determined |
| Lokalisation |
Bacterial rods and byproducts |
Mycobacterium tuberculosis
|
Biocare Medical |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
ACI140C |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
- |
| Positivkontrolle |
Tubercolosis infected lung |
| Verdünnung |
- |
| Isotyp |
not determined |
| Lokalisation |
Bacterial rods and byproducts |
Mycobacterium tuberculosis
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API140AA |
-
|
| Host |
Monospecific Rabbit |
| Klon |
ZR109 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
| Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
1 ml |
Concentrate |
CE/IVD |
Z2411RL |
-
|
| Host |
Monospecific Rabbit |
| Klon |
ZR109 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain. |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
| Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
7 ml |
Ready-to-use |
CE/IVD |
Z2411RP |
-
|
| Host |
Monospecific Rabbit |
| Klon |
ZR109 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
| Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
0.5 ml |
Concentrate |
CE/IVD |
Z2411RS |
-
|
| Host |
Monospecific Rabbit |
| Klon |
ZR109 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
| Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZR109 |
0.1 ml |
Concentrate |
CE/IVD |
Z2411RT |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM202 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
| Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
1 ml |
Concentrate |
CE/IVD |
Z2485ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM202 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain. |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
| Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
7 ml |
Ready-to-use |
CE/IVD |
Z2485MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM202 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
| Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
0.5 ml |
Concentrate |
CE/IVD |
Z2485MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM202 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Brain. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant fragment (around aa 150-250) of human MBP |
| Lokalisation |
Cytoplasm |
Myelin Basic Protein (MBP)
|
Zeta Corporation |
ZM202 |
0.1 ml |
Concentrate |
CE/IVD |
Z2485MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
N/A |
| Positivkontrolle |
Tissue with inflammatory proces (tonsil, colon cancer) |
| Verdünnung |
- |
| Isotyp |
not determined |
| Lokalisation |
Cytoplasmic |
Myeloperoxidase
|
Biocare Medical |
polyclonal |
25 ml |
Ready-to-use |
CE/IVD |
PP023H |
-
|
| Host |
Mouse |
| Klon |
ZM352 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, bone marrow |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b/κ |
| Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
| Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
1 ml |
Concentrate |
CE/IVD |
Z2680ML |
-
|
| Host |
Mouse |
| Klon |
ZM352 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, bone marrow |
| Verdünnung |
- |
| Isotyp |
IgG2b/κ |
| Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
| Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
7 ml |
Ready-to-use |
CE/IVD |
Z2680MP |
-
|
| Host |
Mouse |
| Klon |
ZM352 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, bone marrow |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b/κ |
| Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
| Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
0.5 ml |
Concentrate |
CE/IVD |
Z2680MS |
-
|
| Host |
Mouse |
| Klon |
ZM352 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, bone marrow |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b/κ |
| Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
| Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
0.1 ml |
Concentrate |
CE/IVD |
Z2680MT |
-
|
| Host |
Mouse |
| Klon |
2C7 |
| Format |
Purified |
| Methode |
F, P, EL, WB, FL |
| Positivkontrolle |
Bone Marrow |
| Verdünnung |
1:500 - 1:1000 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human myeloperoxidase |
Myeloperoxidase (MPO, pANCA)
|
Zytomed Systems GmbH |
2C7 |
200 µg |
Purified |
RUO |
613-0318 |
-
|
| Host |
Mouse |
| Klon |
2C7 |
| Format |
Purified |
| Methode |
F, P, FL |
| Positivkontrolle |
Bone Marrow |
| Verdünnung |
1:500 - 1:1000 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human myeloperoxidase |
Myeloperoxidase (MPO, pANCA)
|
Zytomed Systems GmbH |
2C7 |
20 µg |
Purified |
RUO |
613-0319 |
-
|